ArticleToxicology reports2026
Phloridzin mitigates bleomycin-elicited lung fibrosis in Wistar rats: The interplay between antioxidant defenses, inflammatory processes, transforming growth factor beta 1, and autophagy.
Article in Toxicology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis is a serious complication that limits the clinical use of bleomycin (BLM). This study investigated the protective role of phloridzin (PZ) against BLM-induced pulmonary fibrosis in rats. In a rat model of BLM-elicited lung fibrosis, PZ was administered daily at two dose levels for 35 days, beginning 7 days before BLM treatment. PZ significantly reduced the elevated total leukocyte count, neutrophil and lymphocyte percentages, and lactate dehydrogenase (LDH) activity in the bronchoalveolar lavage fluid (BALF), while increasing BALF macrophage levels. It also lowered malondialdehyde and increased glutathione concentrations. Furthermore, PZ pre-treatment suppressed transforming growth factor-beta 1, interleukin-1β, and nuclear factor-kappa B, while reducing cleaved caspase-3 expression and restoring beclin-1 tissue levels. Histopathological analysis confirmed these protective effects. Taken together, PZ mitigated oxidative stress, inflammation, and apoptosis, while supporting autophagic activity, thereby demonstrating a strong protective effect against BLM-induced lung fibrosis. Importantly, this work provides the first evidence that PZ may counteract multiple pathological mechanisms of BLM-elicited lung toxicity, positioning it as a promising candidate for therapeutic intervention in drug-induced pulmonary fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.